ECSP066795A - Compuestos novedosos como inhibidores de ns3 serina proteasa del virus de hepatitis c - Google Patents

Compuestos novedosos como inhibidores de ns3 serina proteasa del virus de hepatitis c

Info

Publication number
ECSP066795A
ECSP066795A EC2006006795A ECSP066795A ECSP066795A EC SP066795 A ECSP066795 A EC SP066795A EC 2006006795 A EC2006006795 A EC 2006006795A EC SP066795 A ECSP066795 A EC SP066795A EC SP066795 A ECSP066795 A EC SP066795A
Authority
EC
Ecuador
Prior art keywords
hepatitis
virus
inhibitors
new compounds
compounds
Prior art date
Application number
EC2006006795A
Other languages
English (en)
Inventor
Frank Bennett
Stephane L Bogen
F George Njoroge
Ashok Arasappan
Kevin X Chen
Srikanth Venkatraman
Wanli Wu
Latha G Nair
Viyyoor Moopil Girijavallabhan
Melissa L Blackman
Mousumi Sannigrahi
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of ECSP066795A publication Critical patent/ECSP066795A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

La presente invención describe novedosos compuestos los cuales tienen actividad inhibitoria de la proteasa del VHC así como también métodos para preparar ese tipo de compuestos. En otra realización, la invención describe composiciones farmacéuticas que comprende ese tipo de compuestos así como también métodos para su utilización para tratar trastornos asociados con la proteasa del VHC
EC2006006795A 2004-02-27 2006-08-25 Compuestos novedosos como inhibidores de ns3 serina proteasa del virus de hepatitis c ECSP066795A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54850704P 2004-02-27 2004-02-27

Publications (1)

Publication Number Publication Date
ECSP066795A true ECSP066795A (es) 2006-11-16

Family

ID=34962171

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006795A ECSP066795A (es) 2004-02-27 2006-08-25 Compuestos novedosos como inhibidores de ns3 serina proteasa del virus de hepatitis c

Country Status (16)

Country Link
US (3) US7192957B2 (es)
EP (1) EP1748983A2 (es)
JP (1) JP2007525510A (es)
KR (1) KR20060127162A (es)
CN (1) CN1946691A (es)
AR (1) AR047902A1 (es)
AU (1) AU2005222055A1 (es)
BR (1) BRPI0508095A (es)
CA (1) CA2557247A1 (es)
EC (1) ECSP066795A (es)
IL (1) IL177545A0 (es)
NO (1) NO20064356L (es)
RU (1) RU2006134005A (es)
TW (1) TW200602037A (es)
WO (1) WO2005087721A2 (es)
ZA (1) ZA200607104B (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7635694B2 (en) * 2004-02-27 2009-12-22 Schering Corporation Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease
US8119602B2 (en) 2005-06-02 2012-02-21 Schering Corporation Administration of HCV protease inhibitors in combination with food to improve bioavailability
US20070021351A1 (en) * 2005-06-02 2007-01-25 Schering Corporation Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor
US20060281689A1 (en) * 2005-06-02 2006-12-14 Schering Corporation Method for modulating activity of HCV protease through use of a novel HCV protease inhibitor to reduce duration of treatment period
US20060275366A1 (en) * 2005-06-02 2006-12-07 Schering Corporation Controlled-release formulation
US20070237818A1 (en) * 2005-06-02 2007-10-11 Malcolm Bruce A Controlled-release formulation of HCV protease inhibitor and methods using the same
US20060276406A1 (en) * 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis C virus
WO2006130607A2 (en) * 2005-06-02 2006-12-07 Schering Corporation Controlled-release formulation useful for treating disorders associated with hepatitis c virus
US20060276404A1 (en) * 2005-06-02 2006-12-07 Anima Ghosal Medicaments and methods combining a HCV protease inhibitor and an AKR competitor
NZ563365A (en) * 2005-06-02 2011-02-25 Schering Corp Combination of HCV protease inhibitors with a surfactant
WO2006130554A2 (en) * 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis c virus
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
WO2007106317A2 (en) * 2006-03-03 2007-09-20 Schering Corporation Pharmaceutical combinations of hcv-protease and -ires inhibitors
WO2007120595A2 (en) * 2006-04-11 2007-10-25 Novartis Ag Amines for the treatment of hcv
ES2543840T3 (es) * 2006-04-11 2015-08-24 Novartis Ag Inhibidores espirocíclicos del VHC/VIH y sus usos
US20080045530A1 (en) * 2006-04-11 2008-02-21 Trixi Brandl Organic Compounds and Their Uses
BRPI0710183A2 (pt) * 2006-04-11 2011-08-09 Novartis Ag compostos orgánicos e seus usos
BRPI0712021A2 (pt) 2006-05-23 2012-01-03 Irm Llc composto e composiÇÕes como inibidores da protease ativadora de canal
RU2009109355A (ru) 2006-08-17 2010-09-27 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) Ингибиторы вырусной полимеразы
WO2008073282A2 (en) 2006-12-07 2008-06-19 Schering Corporation Ph sensitive matrix formulation
CN101600428A (zh) 2007-02-09 2009-12-09 Irm责任有限公司 作为通道活化蛋白酶抑制剂的化合物和组合物
FR2914920B1 (fr) 2007-04-11 2011-09-09 Clariant Specialty Fine Chem F Procede de deacetalisation d'alpha-aminoacetals.
US8242140B2 (en) 2007-08-03 2012-08-14 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
CN104016970A (zh) 2007-10-10 2014-09-03 诺华股份有限公司 螺环吡咯烷类与其对抗hcv和hiv感染的应用
US8476257B2 (en) 2007-12-19 2013-07-02 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
EP2250174B1 (en) 2008-02-04 2013-08-28 IDENIX Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US8188137B2 (en) 2008-08-15 2012-05-29 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
SG172848A1 (en) 2009-01-07 2011-08-29 Scynexis Inc Cyclosporine derivative for use in the treatment of hcv and hiv infection
US8102720B2 (en) * 2009-02-02 2012-01-24 Qualcomm Incorporated System and method of pulse generation
JP5690286B2 (ja) 2009-03-04 2015-03-25 イデニク プハルマセウティカルス，インコーポレイテッド ホスホチオフェン及びホスホチアゾールｈｃｖポリメラーゼ阻害剤
US8377962B2 (en) 2009-04-08 2013-02-19 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) * 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
WO2010138791A1 (en) 2009-05-29 2010-12-02 Schering Corporation Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
AR077712A1 (es) 2009-08-05 2011-09-14 Idenix Pharmaceuticals Inc Inhibidores de serina proteasa macrociclica
WO2011063076A1 (en) 2009-11-19 2011-05-26 Itherx Pharmaceuticals, Inc. Methods of treating hepatitis c virus with oxoacetamide compounds
JP2013512246A (ja) 2009-11-25 2013-04-11 メルク・シャープ・アンド・ドーム・コーポレーション ウイルス疾患治療に有用な縮合型三環式化合物およびその誘導体
MY159958A (en) 2009-12-18 2017-02-15 Idenix Pharmaceuticals Inc 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
US20130156731A1 (en) 2009-12-22 2013-06-20 Kevin X. Chen Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas
MA34147B1 (fr) 2010-03-09 2013-04-03 Merck Sharp & Dohme Composes tricycliques fusionnes de silyle et leurs methodes d'utilisation dans le cadre du traitement de maladies virales
CA2805440A1 (en) 2010-07-26 2012-02-09 Merck Sharp & Dohme Corp. Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
US9254292B2 (en) 2010-09-29 2016-02-09 Merck Sharp & Dohme Corp. Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
WO2012109398A1 (en) 2011-02-10 2012-08-16 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
EP2696681B1 (en) 2011-04-13 2018-10-03 Merck Sharp & Dohme Corp. 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
US9156872B2 (en) 2011-04-13 2015-10-13 Merck Sharp & Dohme Corp. 2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2013033899A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
WO2013033901A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
WO2013033900A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
EP2755981A4 (en) 2011-09-14 2015-03-25 Merck Sharp & Dohme HETEROCYCLIC COMPOUNDS CONTAINING SILYL AND METHODS OF USING THE SAME FOR TREATING VIRAL DISEASES
US20160229866A1 (en) 2013-09-20 2016-08-11 Idenix Pharmaceuticals Inc. Hepatitis c virus inhibitors
EP3063140A4 (en) 2013-10-30 2017-11-08 Merck Sharp & Dohme Corp. Pseudopolymorphs of an hcv ns5a inhibitor and uses thereof
WO2015134561A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
EP3114122A1 (en) 2014-03-05 2017-01-11 Idenix Pharmaceuticals LLC Solid forms of a flaviviridae virus inhibitor compound and salts thereof
EP3759109B1 (en) * 2018-02-26 2023-08-30 Gilead Sciences, Inc. Substituted pyrrolizine compounds as hbv replication inhibitors
WO2023133174A1 (en) * 2022-01-07 2023-07-13 Merck Sharp & Dohme Llc Protease inhibitors for treating or preventing coronavirus infection

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2012739T5 (es) 1987-11-18 2001-12-01 Chiron Corp Diagnosticos para nanbv.
DE69024378T2 (de) 1989-02-01 1996-09-12 Asahi Glass Co Ltd Azeotrope oder azeotropähnliche Zusammensetzung auf der Basis von Chlorfluorkohlenwasserstoffen
CA2079105C (en) 1990-04-04 2000-06-13 Michael Houghton Hepatitis c virus protease
US5922757A (en) 1996-09-30 1999-07-13 The Regents Of The University Of California Treatment and prevention of hepatic disorders
JP4080541B2 (ja) 1996-10-18 2008-04-23 バーテックス ファーマシューティカルズ インコーポレイテッド セリンプロテアーゼ、特にｃ型肝炎ウイルスｎｓ３プロテアーゼの阻害因子
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
EP1012180B1 (en) 1997-08-11 2004-12-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor peptide analogues
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
AR022061A1 (es) 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US6608027B1 (en) * 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
JP2001049593A (ja) 1999-07-22 2001-02-20 E I Du Pont De Nemours & Co 全芳香族合成繊維からなる繊維紙及びその製造方法及び積層板
AU2001251165A1 (en) 2000-04-03 2001-10-15 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
AR029903A1 (es) 2000-04-05 2003-07-23 Schering Corp Inhibidores macrociclicos de la ns3-serina proteasa, del virus de la hepatitis c, que comprenden partes p2 n-ciclicas, composiciones farmaceuticas y utilizacion de los mismos para la manufactura de un medicamento
CN1432022A (zh) 2000-04-19 2003-07-23 先灵公司 含有烷基和芳基丙氨酸p2部分的丙型肝炎病毒的大环ns3－丝氨酸蛋白酶抑制剂
WO2002008251A2 (en) 2000-07-21 2002-01-31 Corvas International, Inc. Peptides as ns3-serine protease inhibitors of hepatitis c virus
CZ2003195A3 (cs) 2000-07-21 2003-04-16 Schering Corporation Peptidové inhibitory serinové proteázy NS3 a farmaceutický prostředek
US7244721B2 (en) * 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
AR029851A1 (es) 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
AR034127A1 (es) 2000-07-21 2004-02-04 Schering Corp Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
US7012066B2 (en) * 2000-07-21 2006-03-14 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
MXPA03005219A (es) * 2000-12-12 2003-09-25 Schering Corp Peptidos diarilicos como inhibidores de ns3-serina proteasa en hepatitis de virus c.
NZ531681A (en) * 2001-10-24 2007-05-31 Vertex Pharma Inhibitors of serine protease, particularly hepatitis C virus NS3-NS4A protease, incorporating a fused ring system
PE20030857A1 (es) 2002-01-23 2003-10-25 Schering Corp Compuestos como inhibidores de la proteasa serina ns3 del virus de la hepatitis c
ATE438622T1 (de) * 2004-02-27 2009-08-15 Schering Corp 3,4-(cyclopentyl)kondensierte prolinverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus
WO2005085242A1 (en) * 2004-02-27 2005-09-15 Schering Corporation Novel ketoamides with cyclic p4's as inhibitors of ns3 serine protease of hepatitis c virus

Also Published As

Publication number Publication date
US20070049536A1 (en) 2007-03-01
IL177545A0 (en) 2006-12-10
US7192957B2 (en) 2007-03-20
TW200602037A (en) 2006-01-16
EP1748983A2 (en) 2007-02-07
US7718691B2 (en) 2010-05-18
JP2007525510A (ja) 2007-09-06
US20050288233A1 (en) 2005-12-29
US7759499B2 (en) 2010-07-20
CN1946691A (zh) 2007-04-11
NO20064356L (no) 2006-11-24
KR20060127162A (ko) 2006-12-11
CA2557247A1 (en) 2005-09-22
WO2005087721A2 (en) 2005-09-22
BRPI0508095A (pt) 2007-07-17
WO2005087721A3 (en) 2005-11-10
US20070032434A1 (en) 2007-02-08
RU2006134005A (ru) 2008-04-10
AU2005222055A1 (en) 2005-09-22
ZA200607104B (en) 2008-09-25
AR047902A1 (es) 2006-03-01

Similar Documents

Publication Publication Date Title
ECSP066795A (es) Compuestos novedosos como inhibidores de ns3 serina proteasa del virus de hepatitis c
ECSP066792A (es) Cetoamidas novedosas con p4 cíclicos como inhibidores de ns3 serina proteasa del virus de hepatitis c
ECSP066794A (es) Nuevos compuestos como inhibidores de serina proteasa ns3 del virus de la hepatitis c
ECSP066626A (es) Nuevos inhibidores de la ns3/ns4a serina proteasa del virus de la hepatitis c
ECSP099685A (es) Compuestos de azufre como inhibidores de la serina proteasa ns3 del virus de la hepatitis c
ECSP066791A (es) Compuestos azufrados como inhibidores de la serina proteasa ns3 del virus de la hepatitis c
ECSP045191A (es) "nuevos péptidos como inhibidores de la proteasa serina ns3 del virus de la hepatitis c"
ECSP034439A (es) Nuevos peptidos como inhibidores de ns-3-serina proteasa del virus de la hepatitis c
ECSP034438A (es) Nuevos peptidos como inhibidores de ns-3-serina proteasa del virus de la hepatitis c
AR029851A1 (es) Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
MX2009010207A (es) Peptidos de hidrazido como inhibidores de proteasa ns3 de virus de hepatitis c.
ATE513844T1 (de) Acylsulfonamidverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus
NI200900069A (es) Inhibidores de la proteasa ns3 del hcv
GT200600317A (es) Inhibidores de la proteasa ns3 del vhc
BR112014000792A2 (pt) compostos de piperidinila para uso como inibidores da tanquirase
CL2012001176A1 (es) Compuestos derivados de bencimidazol-imidazol, inhibidores del virus de la hepatitis c (hcv); composición farmacéutica que los comprende; combinación farmacéutica; uso en la prevención o tratamiento de infección de hcv.
MX2010004704A (es) Inhibidores macrociclicos de la ns3 serina proteasa del virus de la hepatitis c.
EA201171174A1 (ru) Ингибиторы репликации вируса гепатита c
CO6400192A2 (es) Inhibidores del virus de la hepatitis c
MX2009010205A (es) Inhibidores de cetoamida p1-no epimerizables de proteasa ns3 de virus de hepatitis c.
CO6190510A2 (es) Inhibidores del virus de la hepatitis c
WO2015095735A3 (en) Vaccine compositions and uses thereof
WO2013106689A8 (en) Hcv ns3 protease inhibitors
BR112014013972A8 (pt) inibidores de hcv nssa
MX2013004906A (es) Nuevos inhibidores especificos de la proteasa ns3 de hcv.